SonALAsense is a clinical-stage company developing ALA sonodynamic therapy (SDT) as a first-in-class, non-invasive drug-device combination for the treatment of recurrent glioblastoma multiforme (rGBM) and other deadly cancers. SDT utilizes MRI-guided focused ultrasound (the device) in combination with aminolevulinic acid (a drug) to selectively target and kill tumor cells.
Location: United States, California, Berkeley
Member count: 1-10
Total raised: $20.1M
Founded date: 2019
Investors 1
| Date | Name | Website |
| 28.07.2023 | Keiretsu Forum | keiretsuforum.... |
Funding Rounds 1
| Date | Series | Amount | Investors | Deal News |
| 05.01.2022 | - | $20.1M | - | - |